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Background
Observational cohort studies and a secondary prevention trial have shown an in-
verse association between adherence to the Mediterranean diet and cardiovascular 
risk. We conducted a randomized trial of this diet pattern for the primary preven-
tion of cardiovascular events.
Methods
In a multicenter trial in Spain, we randomly assigned participants who were at high 
cardiovascular risk, but with no cardiovascular disease at enrollment, to one of 
three diets: a Mediterranean diet supplemented with extra-virgin olive oil, a Medi-
terranean diet supplemented with mixed nuts, or a control diet (advice to reduce 
dietary fat). Participants received quarterly individual and group educational ses-
sions and, depending on group assignment, free provision of extra-virgin olive oil, 
mixed nuts, or small nonfood gifts. The primary end point was the rate of major 
cardiovascular events (myocardial infarction, stroke, or death from cardiovascular 
causes). On the basis of the results of an interim analysis, the trial was stopped 
after a median follow-up of 4.8 years.
Results
A total of 7447 persons were enrolled (age range, 55 to 80 years); 57% were women. 
The two Mediterranean-diet groups had good adherence to the intervention, ac-
cording to self-reported intake and biomarker analyses. A primary end-point event 
occurred in 288 participants. The multivariable-adjusted hazard ratios were 0.70 
(95% confidence interval [CI], 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the 
group assigned to a Mediterranean diet with extra-virgin olive oil (96 events) and 
the group assigned to a Mediterranean diet with nuts (83 events), respectively, ver-
sus the control group (109 events). No diet-related adverse effects were reported.
Conclusions
Among persons at high cardiovascular risk, a Mediterranean diet supplemented 
with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular 
events. (Funded by the Spanish government’s Instituto de Salud Carlos III and oth-
ers; Controlled-Trials.com number, ISRCTN35739639.)
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The traditional Mediterranean diet is characterized by a high intake of olive oil, fruit, nuts, vegetables, and cereals; a 
moderate intake of fish and poultry; a low intake 
of dairy products, red meat, processed meats, 
and sweets; and wine in moderation, consumed 
with meals.1 In observational cohort studies2,3 
and a secondary prevention trial (the Lyon Diet 
Heart Study),4 increasing adherence to the Medi-
terranean diet has been consistently beneficial 
with respect to cardiovascular risk.2-4 A system-
atic review ranked the Mediterranean diet as the 
most likely dietary model to provide protection 
against coronary heart disease.5 Small clinical 
trials have uncovered plausible biologic mecha-
nisms to explain the salutary effects of this food 
pattern.6-9 We designed a randomized trial to 
test the efficacy of two Mediterranean diets (one 
supplemented with extra-virgin olive oil and an-
other with nuts), as compared with a control diet 
(advice on a low-fat diet), on primary cardiovas-
cular prevention.
Me thods
Study design
The PREDIMED trial (Prevención con Dieta Med-
iterránea) was a parallel-group, multicenter, ran-
domized trial. Details of the trial design are pro-
vided elsewhere.10-12 The trial was designed and 
conducted by the authors, and the protocol was 
approved by the institutional review boards at all 
study locations. The authors vouch for the accu-
racy and completeness of the data and all analy-
ses and for the fidelity of this report to the pro-
tocol, which is available with the full text of this 
article at NEJM.org.
Supplemental foods were donated, including 
extra-virgin olive oil (by Hojiblanca and Patrimo-
nio Comunal Olivarero, both in Spain), walnuts 
(by the California Walnut Commission), al-
monds (by Borges, in Spain), and hazelnuts (by 
La Morella Nuts, in Spain). None of the sponsors 
had any role in the trial design, data analysis, or 
reporting of the results.
Participant Selection and Randomization
Eligible participants were men (55 to 80 years of 
age) and women (60 to 80 years of age) with no 
cardiovascular disease at enrollment, who had 
either type 2 diabetes mellitus or at least three 
of the following major risk factors: smoking, 
hypertension, elevated low-density lipoprotein 
cholesterol levels, low high-density lipoprotein 
cholesterol levels, overweight or obesity, or a 
family history of premature coronary heart dis-
ease. Detailed enrollment criteria are provided 
in the Supplementary Appendix, available at NEJM 
.org. All participants provided written informed 
 consent.
Beginning on October 1, 2003, participants 
were randomly assigned, in a 1:1:1 ratio, to one 
of three dietary intervention groups: a Mediter-
ranean diet supplemented with extra-virgin olive 
oil, a Mediterranean diet supplemented with 
nuts, or a control diet. Randomization was per-
formed centrally by means of a computer-gener-
ated random-number sequence.
Interventions and Measurements
The dietary intervention8,10-13 is detailed in the 
Supplementary Appendix. The specific recom-
mended diets are summarized in Table 1. Par-
ticipants in the two Mediterranean-diet groups 
received either extra-virgin olive oil (approxi-
mately 1 liter per week) or 30 g of mixed nuts per 
day (15 g of walnuts, 7.5 g of hazelnuts, and 
7.5 g of almonds) at no cost, and those in the 
control group received small nonfood gifts. No 
total calorie restriction was advised, nor was 
physical activity promoted.
For participants in the two Mediterranean-
diet groups, dietitians ran individual and group 
dietary-training sessions at the baseline visit and 
quarterly thereafter. In each session, a 14-item 
dietary screener was used to assess adherence to 
the Mediterranean diet8,14 (Table S1 in the Sup-
plementary Appendix) so that personalized ad-
vice could be provided to the study participants 
in these groups.
Participants in the control group also re-
ceived dietary training at the baseline visit and 
completed the 14-item dietary screener used to 
assess baseline adherence to the Mediterranean 
diet. Thereafter, during the first 3 years of the 
trial, they received a leaflet explaining the low-
fat diet (Table S2 in the Supplementary Appen-
dix) on a yearly basis. However, the realization 
that the more infrequent visit schedule and less 
intense support for the control group might be 
limitations of the trial prompted us to amend 
the protocol in October 2006. Thereafter, par-
ticipants assigned to the control diet received 
personalized advice and were invited to group 
sessions with the same frequency and intensity 
as those in the Mediterranean-diet groups, with 
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the use of a separate 9-item dietary screener 
(Table S3 in the Supplementary Appendix).
A general medical questionnaire, a 137-item 
validated food-frequency questionnaire,15 and 
the Minnesota Leisure-Time Physical Activity 
Questionnaire were administered on a yearly 
basis.10 Information from the food-frequency 
questionnaire was used to calculate intake of 
energy and nutrients. Weight, height, and waist 
circumference were directly measured.16 Bio-
markers of compliance, including urinary hy-
droxytyrosol levels (to confirm compliance in 
the group receiving extra-virgin olive oil) and 
plasma alpha-linolenic acid levels (to confirm 
compliance in the group receiving mixed nuts), 
were measured in random subsamples of par-
ticipants at 1, 3, and 5 years (see the Supplemen-
tary Appendix).
End Points
The primary end point was a composite of myo-
cardial infarction, stroke, and death from cardio-
vascular causes. Secondary end points were 
stroke, myocardial infarction, death from cardio-
vascular causes, and death from any cause. We 
used four sources of information to identify end 
points: repeated contacts with participants, con-
tacts with family physicians, a yearly review of 
medical records, and consultation of the Nation-
al Death Index. All medical records related to 
end points were examined by the end-point adju-
dication committee, whose members were un-
aware of the study-group assignments. Only end 
points that were confirmed by the adjudication 
committee and that occurred between October 1, 
2003, and December 1, 2010, were included in 
the analyses. The criteria for adjudicating pri-
mary and secondary end points are detailed in 
the Supplementary Appendix.
Statistical Analysis
We initially estimated that a sample of 9000 par-
ticipants would be required to provide statistical 
power of 80% to detect a relative risk reduction 
of 20% in each Mediterranean-diet group versus 
the control-diet group during a 4-year follow-up 
period, assuming an event rate of 12% in the 
control group.10,17 In April 2008, on the advice of 
the data and safety monitoring board and on the 
basis of lower-than-expected rates of end-point 
events, the sample size was recalculated as 7400 
participants, with the assumption of a 6-year 
follow-up period and underlying event rates of 
Table 1. Summary of Dietary Recommendations to Participants in the 
Mediterranean-Diet Groups and the Control-Diet Group.
Food Goal
Mediterranean diet
Recommended
Olive oil* ≥4 tbsp/day
Tree nuts and peanuts† ≥3 servings/wk
Fresh fruits ≥3 servings/day
Vegetables ≥2 servings/day
Fish (especially fatty fish), seafood ≥3 servings/wk
Legumes ≥3 servings/wk
Sofrito‡ ≥2 servings/wk
White meat Instead of red meat
Wine with meals (optionally, only for  habitual 
drinkers)
≥7 glasses/wk
Discouraged
Soda drinks <1 drink/day
Commercial bakery goods, sweets, and pastries§ <3 servings/wk
Spread fats <1 serving/day
Red and processed meats <1 serving/day
Low-fat diet (control)
Recommended
Low-fat dairy products ≥3 servings/day
Bread, potatoes, pasta, rice ≥3 servings/day
Fresh fruits ≥3 servings/day
Vegetables ≥2 servings/day
Lean fish and seafood ≥3 servings/wk
Discouraged
Vegetable oils (including olive oil) ≤2 tbsp/day
Commercial bakery goods, sweets, and pastries§ ≤1 serving/wk
Nuts and fried snacks ≤1 serving /wk
Red and processed fatty meats ≤1 serving/wk
Visible fat in meats and soups¶ Always remove
Fatty fish, seafood canned in oil ≤1 serving/wk
Spread fats ≤1 serving/wk
Sofrito‡ ≤2 servings/wk
* The amount of olive oil includes oil used for cooking and salads and oil con-
sumed in meals eaten outside the home. In the group assigned to the Medi-
terranean diet with extra-virgin olive oil, the goal was to consume 50 g (ap-
proximately 4 tbsp) or more per day of the polyphenol-rich olive oil supplied, 
instead of the ordinary refined variety, which is low in polyphenols.
† For participants assigned to the Mediterranean diet with nuts, the recommend-
ed consumption was one daily serving (30 g, composed of 15 g of walnuts, 
7.5 g of almonds, and 7.5 g of hazelnuts).
‡ Sofrito is a sauce made with tomato and onion, often including garlic and aro-
matic herbs, and slowly simmered with olive oil.
§ Commercial bakery goods, sweets, and pastries (not homemade) included 
cakes, cookies, biscuits, and custard.
¶ Participants were advised to remove the visible fat (or the skin) of chicken, 
duck, pork, lamb, or veal before cooking and the fat of soups, broths, and 
cooked meat dishes before consumption.
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8.8% and 6.6% in the control and intervention 
groups, respectively. Power curves under several 
assumptions can be found in Figure S1 in the 
Supplementary Appendix.
Yearly interim analyses began after a median 
of 2 years of follow-up. With the use of O’Brien–
Fleming stopping boundaries, the P values for 
stopping the trial at each yearly interim analysis 
were 5×10−6, 0.001, 0.009, and 0.02 for benefit 
and 9×10−5, 0.005, 0.02, and 0.05 for adverse ef-
fects.18 The stopping boundary for the benefit of 
the Mediterranean diets with respect to the pri-
mary end point was crossed at the fourth inter-
im evaluation; on July 22, 2011, the data and 
safety monitoring board recommended stopping 
the trial on the basis of end points documented 
through December 1, 2010.
All primary analyses were performed on an 
intention-to-treat basis by two independent ana-
lysts. Time-to-event data were analyzed with the 
use of Cox models with two dummy variables 
(one for the Mediterranean diet with extra-virgin 
olive oil and another for the Mediterranean diet 
with nuts) to obtain two hazard ratios for the 
comparison with the control group. To account 
for small imbalances in risk factors at baseline 
among the groups, Cox regression models were 
used to adjust for sex, age, and baseline risk fac-
tors. We tested the proportionality of hazards 
with the use of time-varying covariates. All 
analyses were stratified according to center. Pre-
specified subgroup analyses were conducted ac-
cording to sex, age, body-mass index (BMI), 
cardiovascular-risk-factor status, and baseline 
adherence to the Mediterranean diet. Sensitivity 
analyses were conducted under several assump-
tions, including imputation of data for missing 
values and participants who dropped out (see the 
Supplementary Appendix).
R esult s
Baseline Characteristics of the Study 
Participants
From October 2003 through June 2009, a total of 
8713 candidates were screened for eligibility, and 
Table 2. Baseline Characteristics of the Participants According to Study Group.*
Characteristic
Mediterranean  
Diet with EVOO
(N = 2543)
Mediterranean 
Diet with Nuts
(N = 2454)
Control Diet
(N = 2450)
Female sex — no. (%)† 1493 (58.7) 1326 (54.0) 1463 (59.7)
Age — yr† 67.0±6.2 66.7±6.1 67.3±6.3
Race or ethnic group — no. (%)
White, from Europe 2470 (97.1) 2390 (97.4) 2375 (96.9)
Hispanic, from Central or South America 35 (1.4) 29 (1.2) 38 (1.6)
Other 38 (1.5) 35 (1.4) 37 (1.5)
Smoking status — no. (%)
Never smoked 1572 (61.8) 1465 (59.7) 1527 (62.3)
Former smoker 618 (24.3) 634 (25.8) 584 (23.8)
Current smoker 353 (13.9) 355 (14.5) 339 (13.8)
Body-mass index†‡
Mean 29.9±3.7 29.7±3.8 30.2±4.0
<25 — no. (%) 195 (7.7) 204 (8.3) 164 (6.7)
25–30 — no. (%) 1153 (45.3) 1163 (47.4) 1085 (44.3)
>30 — no. (%) 1195 (47.0) 1087 (44.3) 1201 (49.0)
Waist circumference — cm 100±10 100±11 101±11
Waist-to-height ratio†§ 0.63±0.06 0.63±0.06 0.63±0.07
Hypertension — no. (%)¶ 2088 (82.1) 2024 (82.5) 2050 (83.7)
Type 2 diabetes — no. (%)†‖ 1282 (50.4) 1143 (46.6) 1189 (48.5)
Dyslipidemia — no. (%)** 1821 (71.6) 1799 (73.3) 1763 (72.0)
Family history of premature CHD — no. (%)†† 576 (22.7) 532 (21.7) 560 (22.9)
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7447 were randomly assigned to one of the three 
study groups (Fig. S2 in the Supplementary Ap-
pendix). Their baseline characteristics according 
to study group are shown in Table 2. Drug-treat-
ment regimens were similar for participants in 
the three groups, and they continued to be bal-
anced during the follow-up period (Table S4 in 
the Supplementary Appendix).
Participants were followed for a median of 
4.8 years (interquartile range, 2.8 to 5.8). After 
the initial assessment, 209 participants (2.8%) 
chose not to attend subsequent visits, and their 
follow-up was based on reviews of medical re-
cords. By December 2010, a total of 523 partici-
pants (7.0%) had been lost to follow-up for 2 or 
more years. Dropout rates were higher in the con-
trol group (11.3%) than in the Mediterranean-
diet groups (4.9%) (Fig. S2 in the Supplementary 
Appendix). As compared with participants who 
remained in the trial, those who dropped out 
were younger (by 1.4 years), had a higher BMI 
(the weight in kilograms divided by the square of 
the height in meters; by 0.4), a higher waist-to-
height ratio (by 0.01), and a lower score for ad-
herence to the Mediterranean diet (by 1.0 points 
on the 14-item dietary screener) (P<0.05 for all 
comparisons).
Compliance with the Dietary Intervention
Participants in the three groups reported similar 
adherence to the Mediterranean diet at baseline 
(Table 2, and Fig. S3 in the Supplementary Ap-
pendix) and similar food and nutrient intakes. 
During follow-up, scores on the 14-item Medi-
terranean-diet screener increased for the par-
ticipants in the two Mediterranean-diet groups 
(Fig. S3 in the Supplementary Appendix). There 
were significant differences between these groups 
and the control group in 12 of the 14 items at 
3 years (Table S5 in the Supplementary Appen-
Table 2. (Continued.)
Characteristic
Mediterranean  
Diet with EVOO
(N = 2543)
Mediterranean 
Diet with Nuts
(N = 2454)
Control Diet
(N = 2450)
Medication use — no. (%)
ACE inhibitors 1236 (48.6) 1223 (49.8) 1216 (49.6)
Diuretics† 534 (21.0) 477 (19.4) 562 (22.9)
Other antihypertensive agents 725 (28.5) 710 (28.9) 758 (30.9)
Statins 1039 (40.9) 964 (39.3) 983 (40.1)
Other lipid-lowering agents 121 (4.8) 145 (5.9) 126 (5.1)
Insulin 124 (4.9) 126 (5.1) 134 (5.5)
Oral hypoglycemic agents† 768 (30.2) 680 (27.7) 757 (30.9)
Antiplatelet therapy 475 (18.7) 490 (20.0) 513 (20.9)
Hormone-replacement therapy‡‡ 42 (2.8) 35 (2.6) 39 (2.7)
Score for adherence to Med diet§§ 8.7±2.0 8.7±2.0 8.4±2.1
*  Plus–minus values are means ±SD. ACE denotes angiotensin-converting enzyme, and EVOO extra-virgin olive oil.
† P<0.05 for comparisons between groups.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ The waist-to-height ratio (an index of central obesity) is the waist circumference divided by height.
¶ Hypertension was defined as a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of  
90 mm Hg or higher, or the use of antihypertensive therapy.
‖ Diabetes was defined as a fasting blood glucose level of 126 mg per deciliter (7.0 mmol per liter) or higher on two 
 occasions, a 2-hour plasma glucose level of 200 mg per deciliter (11 mmol per liter) or higher during a 75-g oral glu-
cose-tolerance test, or the use of antidiabetic medication.
** Dyslipidemia was defined as a low-density lipoprotein cholesterol level higher than 160 mg per deciliter (4.1 mmol 
per liter), a high-density lipoprotein cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or lower in men or 50 mg 
per deciliter (1.3 mmol per liter) or lower in women, or the use of lipid-lowering therapy.
†† A family history of premature coronary heart disease (CHD) was defined as a diagnosis of the disease in a male first-
degree relative younger than 55 years of age or in a female first-degree relative younger than 65 years of age.
‡‡ The values for hormone-replacement therapy are for women only.
§§ The score for adherence to the Mediterranean diet is based on the 14-item dietary screener shown in Table S1 in the 
Supplementary Appendix (a score of 0 indicates minimum adherence, and a score of 14 indicates maximum adherence).
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dix). Changes in objective biomarkers also indi-
cated good compliance with the dietary assign-
ments (Fig. S4 and S5 in the Supplementary 
Appendix).
Participants in the two Mediterranean-diet 
groups significantly increased weekly servings of 
fish (by 0.3 servings) and legumes (by 0.4 serv-
ings) in comparison with those in the control 
group (Table S6 in the Supplementary Appendix). 
In addition, participants assigned to a Mediter-
ranean diet with extra-virgin olive oil and those 
assigned to a Mediterranean diet with nuts sig-
nificantly increased their consumption of extra-
virgin olive oil (to 50 and 32 g per day, respec-
tively) and nuts (to 0.9 and 6 servings per week, 
respectively). The main nutrient changes in the 
Mediterranean-diet groups reflected the fat con-
tent and composition of the supplemental foods 
(Tables S7 and S8 in the Supplementary Appen-
dix). No relevant diet-related adverse effects 
were reported (see the Supplementary Appen-
dix). We did not find any significant difference 
in changes in physical activity among the three 
groups.
Table 3. Outcomes According to Study Group.*
End Point
Mediterranean  
Diet with EVOO
(N = 2543)
Mediterranean 
Diet with Nuts
(N = 2454)
Control Diet
(N = 2450) P Value†
Mediterranean 
Diet with EVOO 
vs. Control Diet
Mediterranean 
Diet with Nuts 
vs. Control Diet
Person-yr of follow-up 11,852 10,365 9763
Primary end point‡
No. of events 96 83 109
Crude rate/1000 person-yr (95% CI) 8.1 (6.6–9.9) 8.0 (6.4–9.9) 11.2 (9.2–13.5) 0.009 0.02
Secondary end points
Stroke
No. of events 49 32 58
Crude rate/1000 person-yr (95% CI) 4.1 (3.1–5.5) 3.1 (2.1–4.4) 5.9 (4.5–7.7) 0.03 0.003
Myocardial infarction
No. of events 37 31 38
Crude rate/1000 person-yr (95% CI) 3.1 (2.2–4.3) 3.0 (2.0–4.2) 3.9 (2.8–5.3) 0.31 0.25
Death from cardiovascular causes
No. of events 26 31 30
Crude rate/1000 person-yr (95% CI) 2.2 (1.4–3.2) 3.0 (2.0–4.2) 3.1 (2.1–4.4) 0.15 0.85
Death from any cause
No. of events 118 116 114
Crude rate/1000 person-yr (95% CI) 10.0 (8.2–11.9) 11.2 (9.3–13.4) 11.7 (9.6–14.0) 0.11 0.68
Hazard ratio for each Mediterranean diet  
vs. control (95% CI)
Primary end point
Unadjusted 0.70 (0.53–0.91) 0.70 (0.53–0.94) 1.00 (ref) 0.009 0.02
Multivariable-adjusted 1§ 0.69 (0.53–0.91) 0.72 (0.54–0.97) 1.00 (ref) 0.008 0.03
Multivariable-adjusted 2¶ 0.70 (0.54–0.92) 0.72 (0.54–0.96) 1.00 (ref) 0.01 0.03
Secondary end points‖
Stroke 0.67 (0.46–0.98) 0.54 (0.35–0.84) 1.00 (ref) 0.04 0.006
Myocardial infarction 0.80 (0.51–1.26) 0.74 (0.46–1.19) 1.00 (ref) 0.34 0.22
Death from cardiovascular causes 0.69 (0.41–1.16) 1.01 (0.61–1.66) 1.00 (ref) 0.17 0.98
Death from any cause 0.82 (0.64–1.07) 0.97 (0.74–1.26) 1.00 (ref) 0.15 0.82
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End Points
The median follow-up period was 4.8 years. A 
total of 288 primary-outcome events occurred: 
96 in the group assigned to a Mediterranean diet 
with extra-virgin olive oil (3.8%), 83 in the group 
assigned to a Mediterranean diet with nuts 
(3.4%), and 109 in the control group (4.4%). Tak-
ing into account the small differences in the ac-
crual of person-years among the three groups, 
the respective rates of the primary end point 
were 8.1, 8.0, and 11.2 per 1000 person-years 
(Table 3). The unadjusted hazard ratios were 0.70 
(95% confidence interval [CI], 0.53 to 0.91) for a 
Mediterranean diet with extra-virgin olive oil and 
0.70 (95% CI, 0.53 to 0.94) for a Mediterranean 
diet with nuts (Fig. 1) as compared with the con-
trol diet (P = 0.015, by the likelihood ratio test, 
for the overall effect of the intervention).
The results of multivariate analyses showed a 
similar protective effect of the two Mediterra-
nean diets versus the control diet with respect to 
the primary end point (Table 3). Regarding com-
ponents of the primary end point, only the com-
parisons of stroke risk reached statistical signifi-
cance (Table 3, and Fig. S6 in the Supplementary 
Appendix). The Kaplan–Meier curves for the 
primary end point diverged soon after the trial 
started, but no effect on all-cause mortality was 
apparent (Fig. 1). The results of several sensitiv-
ity analyses were also consistent with the find-
ings of the primary analysis (Table S9 in the 
Supplementary Appendix).
Subgroup Analyses
Reductions in disease risk in the two Mediterra-
nean-diet groups as compared with the control 
group were similar across the prespecified sub-
groups (Fig. 2, and Table S10 in the Supplemen-
tary Appendix). In addition, to account for the 
protocol change in October 2006 whereby the 
intensity of dietary intervention in the control 
group was increased, we compared hazard ratios 
Table 3. (Continued.)
End Point
Mediterranean  
Diet with EVOO
(N = 2543)
Mediterranean 
Diet with Nuts
(N = 2454)
Control Diet
(N = 2450) P Value†
Mediterranean 
Diet with EVOO 
vs. Control Diet
Mediterranean 
Diet with Nuts 
vs. Control Diet
Hazard ratio for Mediterranean diets combined  
vs. control (95% CI)
Primary end point
Unadjusted 0.70 (0.55–0.89) 1 (ref) 0.003
Multivariable-adjusted 1§ 0.71 (0.56–0.90) 1 (ref) 0.004
Multivariable-adjusted 2¶ 0.71 (0.56–0.90) 1 (ref) 0.005
Secondary end points‖
Stroke 0.61 (0.44–0.86) 1 (ref) 0.005
Myocardial infarction 0.77 (0.52–1.15) 1 (ref) 0.20
Death from cardiovascular causes 0.83 (0.54–1.29) 1 (ref) 0.41
Death from any cause 0.89 (0.71–1.12) 1 (ref) 0.32
* CI denotes confidence interval, and ref reference.
† All P values were calculated with the use of Cox proportional-hazards models with robust variance estimators and stratification according to 
recruiting center.
‡ The primary end point was a composite of myocardial infarction, stroke, and death from cardiovascular causes.
§ The primary end point was stratified according to recruiting center and adjusted for sex, age (continuous variable), family history of pre-
mature coronary heart disease (yes or no), and smoking status (never smoked, former smoker, or current smoker).
¶ The primary end point was additionally adjusted for body-mass index (continuous variable), waist-to-height ratio (continuous variable), 
 hypertension at baseline (yes or no), dyslipidemia at baseline (yes or no), and diabetes at baseline (yes or no).
‖ The secondary end points were stratified according to recruiting center and adjusted for sex, age (continuous variable), family history of 
premature coronary heart disease (yes or no), smoking status (never smoked, former smoker, or current smoker), body-mass index (con-
tinuous variable), waist-to-height ratio (continuous variable), hypertension at baseline (yes or no), dyslipidemia at baseline (yes or no), and 
diabetes at baseline (yes or no).
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for the Mediterranean-diet groups (both groups 
merged vs. the control group) before and after 
this date. Adjusted hazard ratios were 0.77 (95% 
CI, 0.59 to 1.00) for participants recruited before 
October 2006 and 0.49 (95% CI, 0.26 to 0.92) for 
those recruited thereafter (P = 0.21 for interaction).
Discussion
In this trial, an energy-unrestricted Mediterra-
nean diet supplemented with either extra-virgin 
olive oil or nuts resulted in an absolute risk re-
duction of approximately 3 major cardiovascular 
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Figure 1. Kaplan–Meier Estimates of the Incidence of Outcome Events in the Total Study Population.
Panel A shows the incidence of the primary end point (a composite of acute myocardial infarction, stroke, and death 
from cardiovascular causes), and Panel B shows total mortality. Hazard ratios were stratified according to center 
(Cox model with robust variance estimators). CI denotes confidence interval, EVOO extra-virgin olive oil, and Med 
Mediterranean.
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events per 1000 person-years, for a relative risk 
reduction of approximately 30%, among high-
risk persons who were initially free of cardiovas-
cular disease. These results support the benefits 
of the Mediterranean diet for cardiovascular risk 
reduction. They are particularly relevant given the 
challenges of achieving and maintaining weight 
loss. The secondary prevention Lyon Diet Heart 
Study also showed a large reduction in rates of 
coronary heart disease events with a modified 
1.0 2.0
Control Diet BetterMediterranean Diets Better
Sex
Male
Female
Age
<70 yr
≥70 yr
Diabetes
No
Yes
Hypertension
No
Yes
Dyslipidemia
No
Yes
Smoking
Never
Ever
Family history of premature CHD
No
Yes
BMI
<25
25–30
>30
Waist
<Median
≥Median
Waist-to-height ratio
<Median
≥Median
Baseline score for adherence to Mediterranean diet
<9 (low)
≥9 (high)
End-point components
Stroke
Myocardial infarction
Death from cardiovascular causes
Combined
Mediterranean Diets Hazard Ratio (95% CI)
Control
DietSubgroup
0.5
P Value for
Interaction
0.62
0.84
0.63
0.06
0.06
0.75
0.97
0.05
0.72
0.82
0.44
no. of participants with primary end-point
event/total no. of participants
64/987107/2178 0.69 (0.51–0.94)
45/146372/2819 0.73 (0.50–1.07)
47/150486/3272 0.73 (0.52–1.05)
62/94693/1725 0.71 (0.51–0.98)
40/126158/2572 0.67 (0.45–1.01)
69/1189121/2425 0.71 (0.53–0.96)
11/40040/885 1.25 (0.64–2.45)
98/2050139/4112 0.65 (0.50–0.84)
36/68777/1377 0.95 (0.64–1.42)
73/1763102/3620 0.60 (0.44–0.80)
54/152780/3037 0.67 (0.47–0.94)
55/92399/1960 0.75 (0.54–1.03)
87/1890144/3889 0.72 (0.55–0.94)
22/56035/1108 0.75 (0.43–1.29)
7/16418/399 0.69 (0.29–1.67)
37/108588/2316 1.04 (0.71–1.54)
65/120173/2282 0.51 (0.37–0.71)
48/117787/2561 0.76 (0.53–1.08)
61/127392/2436 0.67 (0.48–0.93)
47/118281/2549 0.74 (0.52–1.06)
62/126898/2448 0.68 (0.50–0.94)
61/125693/2178 0.81 (0.58–1.12)
48/119486/2819 0.64 (0.45–0.92)
58/245081/4997 0.61 (0.44–0.86)
38/245068/4997 0.77 (0.52–1.15)
30/245057/4997 0.83 (0.54–1.29)
Figure 2. Results of Subgroup Analyses.
Shown are adjusted hazard ratios for the primary end point within specific subgroups. Squares denote hazard ratios; horizontal lines 
represent 95% confidence intervals. Hazard ratios indicate the relative risk in both intervention groups merged together (vs. the control 
group) within each stratum. Hazard ratios were stratified according to recruiting center and were adjusted for sex, age (continuous vari-
able), family history of premature coronary heart disease (CHD) (yes or no), smoking (never smoked, former smoker, or current smok-
er), body-mass index (BMI) (continuous variable), waist-to-height ratio (continuous variable), hypertension at baseline (yes or no), dys-
lipidemia at baseline (yes or no), and diabetes at baseline (yes or no). Scores for adherence to the Mediterranean diet range from 0 to 
14, with higher scores indicating greater adherence.
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Mediterranean diet enriched with alpha-linolenic 
acid (a key constituent of walnuts). That result, 
however, was based on only a few major events.4,19,20
There were small between-group differences 
in some baseline characteristics in our trial, which 
were not clinically meaningful but were statisti-
cally significant, and we therefore adjusted for 
these variables. In fully adjusted analyses, we found 
significant results for the combined cardiovas-
cular end point and for stroke, but not for myo-
cardial infarction alone. This could be due to 
stronger effects on specific risk factors for stroke 
but also to a lower statistical power to identify 
effects on myocardial infarction. Our findings 
are consistent with those of prior observational 
studies of the cardiovascular protective effects 
of the Mediterranean diet,2,5 olive oil,21-23 and 
nuts24,25; smaller trials assessing effects on tra-
ditional cardiovascular risk factors6-9 and novel 
risk factors, such as markers of oxidation, in-
flammation, and endothelial dysfunction6,8,26-28; 
and studies of conditions associated with high 
cardiovascular risk — namely, the metabolic 
syndrome6,16,29 and diabetes.30-32 Thus, a causal 
role of the Mediterranean diet in cardiovascular 
prevention has high biologic plausibility. The 
results of our trial might explain, in part, the 
lower cardiovascular mortality in Mediterranean 
countries than in northern European countries 
or the United States.33
The risk of stroke was reduced significantly 
in the two Mediterranean-diet groups. This is 
consistent with epidemiologic studies that showed 
an inverse association between the Mediterra-
nean diet2,34 or olive-oil consumption22 and in-
cident stroke.
Our results compare favorably with those of 
the Women’s Health Initiative Dietary Modifica-
tion Trial, wherein a low-fat dietary approach 
resulted in no cardiovascular benefit.35 Salient 
components of the Mediterranean diet report-
edly associated with better survival include mod-
erate consumption of ethanol (mostly from wine), 
low consumption of meat and meat products, 
and high consumption of vegetables, fruits, nuts, 
legumes, fish, and olive oil.36,37 Perhaps there is 
a synergy among the nutrient-rich foods includ-
ed in the Mediterranean diet that fosters favor-
able changes in intermediate pathways of car-
diometabolic risk, such as blood lipids, insulin 
sensitivity, resistance to oxidation, inflammation, 
and vasoreactivity.38
Our study has several limitations. First, the 
protocol for the control group was changed half-
way through the trial. The lower intensity of 
dietary intervention for the control group during 
the first few years might have caused a bias to-
ward a benefit in the two Mediterranean-diet 
groups, since the participants in these two groups 
received a more intensive intervention during 
that time. However, we found no significant in-
teraction between the period of trial enrollment 
(before vs. after the protocol change) and the 
benefit in the Mediterranean-diet groups. Sec-
ond, we had losses to follow-up, predominantly 
in the control group, but the participants who 
dropped out had a worse cardiovascular risk pro-
file at baseline than those who remained in the 
study, suggesting a bias toward a benefit in the 
control group. Third, the generalizability of our 
findings is limited because all the study partici-
pants lived in a Mediterranean country and were 
at high cardiovascular risk; whether the results 
can be generalized to persons at lower risk or to 
other settings requires further research.
As with many clinical trials, the observed rates 
of cardiovascular events were lower than antici-
pated, with reduced statistical power to sepa-
rately assess components of the primary end 
point. However, favorable trends were seen for 
both stroke and myocardial infarction. We ac-
knowledge that, even though participants in the 
control group received advice to reduce fat in-
take, changes in total fat were small and the 
largest differences at the end of the trial were in 
the distribution of fat subtypes. The interventions 
were intended to improve the overall dietary pat-
tern, but the major between-group differences 
involved the supplemental items. Thus, extra-
virgin olive oil and nuts were probably respon-
sible for most of the observed benefits of the 
Mediterranean diets. Differences were also ob-
served for fish and legumes but not for other 
food groups. The small between-group differ-
ences in the diets during the trial are probably 
due to the facts that for most trial participants 
the baseline diet was similar to the trial Mediter-
ranean diet and that the control group was given 
recommendations for a healthy diet, suggesting 
a potentially greater benefit of the Mediterra-
nean diet as compared with Western diets.
In conclusion, in this primary prevention trial, 
we observed that an energy-unrestricted Medi-
terranean diet, supplemented with extra-virgin 
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olive oil or nuts, resulted in a substantial reduc-
tion in the risk of major cardiovascular events 
among high-risk persons. The results support 
the benefits of the Mediterranean diet for the 
primary prevention of cardiovascular disease.
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